

11 Apr 2021 |

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda's strategic R&D plans, Cigna's psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 April 2021, including: safety concerns for JAK inhibitors; Takeda's R&D plans; Cigna's psoriasis insurance program; upcoming Phase III readouts to look out for; and an overview of the global R&D pipeline.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[What Will JAK Inhibitor Safety Jitters Mean For Drug Sales?](#)" - Scrip, 7 Apr, 2021.)

(Also see "[Takeda Highlights Rare Neurological Disorder Programs In Wave 1](#)" - Scrip, 6 Apr, 2021.)

(Also see "[Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx](#)" - Scrip, 6 Apr, 2021.)

(Also see "[Five Phase III Data Readouts To Look Out For In Q2](#)" - Scrip, 7 Apr, 2021.)

(Also see "[COVID-19 Accounts For Most Of 2020's Pharma Pipeline Growth](#)" - Scrip, 5 Apr, 2021.)

[Click here to explore this interactive content online](#) 